The Review Of
DIABETIC
STUDIES OPEN ACCESS

Pharmacotherapeutic Management Of Severe Community-Acquired Pneumonia In Elderly Patients With Comorbidities

Saud Homoud Aldagani[1], Zainab Ibrahim Awari [2], Mohammed Moqoid Alharbi[3], Abdulaziz Mohammed Alowayshiz[3], Saeed Saleh Alzahrani[4], Sami Ahmed Almalki[5], Jumanah Faisal Albasri[6], Abdulrhman Edhah Alkhudidy[7], Ikhlas Idris Al Hawsawi[8], Khiriah Mukhtar Hawsawi[9], Abdulaziz mohammed Almutawa[10]

[1]Pharmacy technician, Medical supplies and warehouses, Saudi Arabia.
[2] Pharmacist, King salman medical city - moh, Saudi Arabia.
[3]Specialisation Pharmacy, Branch of the Ministry of Health in Riyadh Region, Saudi Arabia.
[4]Pharmacist, Alqara general hospital, Saudi Arabia.
[5]Pharmacist, Ajyad Emergency Hospital in Makkah, Saudi Arabia.
[6]Pharmacist, Home health care -MOH, Saudi Arabia.
[7]Pharmacy Technician, Al kur Shaddad Health Center, Saudi Arabia.
[8]Pharmacist, King abdulaziz hospital, Saudi Arabia.
[9]Pharmacy technician, Adham General Hospital, Saudi Arabia.
[10]Pharmacist, Directorate of Health Affairs in Jeddah, Saudi Arabia.

Abstract
Community-acquired pneumonia (CAP) affects older adults more than other age groups. This speeds up the disease's progression and makes it harder to treat with drugs. This is especially true for people who have long-term health problems like type 2 diabetes and chronic obstructive pulmonary disease (COPD). This review assembles the latest research on the etiology and management of severe community-acquired pneumonia (CAP). Focusing on antibiotics informed by guidelines and pragmatic clinical considerations. The empirical selection of antibiotics, combination therapy for severe disease, and the transition to oral step-down regimens following clinical stability are all highlighted. The significance of pharmacokinetic and pharmacodynamic parameters was discussed for the safety and efficacy of treatment in elderly patients. It is a encompassing renal function, glycemic control, and potential drug-drug interactions. The review stresses both antimicrobial stewardship and personalized, pharmacist-led treatments to improve outcomes. The data indicates that patient-centered, personalized medication is crucial for managing severe community-acquired pneumonia. Particularly in individuals with multiple comorbidities.

Keywords: Community-acquired pneumonia, Chronic obstructive pulmonary disease, Antibiotic therapy, Sepsis; Pharmacotherapeutic management.

Introduction

In acute bacterial pneumonia, harmful germs get into the alveoli and lung parenchyma and grow there, causing inflammation. These infections make the immune system too complicated, which makes people sick. Patients often have pleuritic chest pain, shortness of breath, coughing up mucus, and a fever. In severe cases, organ failure, meningitis, sepsis, empyema, and necrotizing pneumonia are all possible complications. Pneumonia can exert enduring effects on pulmonary function and overall quality of life in elderly individuals with chronic comorbidities. One of these groups is older people (Anwar et al., 2024).

Pneumonia is one type of lung disease. The Greek word pneumon, which means "lung," is where it comes from. Clinically, it presents as inflammation of the alveolar space and lung parenchyma in one or both lungs. Aspiration and autoimmune processes can also cause changes that are bad for your health. Most of the time, infections are what cause this condition. Bacterial pneumonia is the most common type of pneumonia and a major cause of illness and death around the world. It can be caused by many different types of bacteria. There are many ways to classify things, and each has its own pros and cons when it comes to diagnosis and treatment. The National Institutes of Health (NIH) divides pneumonia

into three groups: atypical pneumonia, community-acquired pneumonia (CAP), and hospital-acquired pneumonia (HAP). A lot of people use this strategy. It also sorts them by how serious risk factors are (Yousaf et al., 2022).
HCAP has more specific groups for pulmonary infections that people get in healthcare settings, like hospitals, dialysis centers, long-term care facilities, and ventilators. The absence of adequate data demonstrating consistent microbiological disparities between HCAP and CAP is the rationale for its exclusion from recent American guidelines. This shows how our understanding of pneumonia epidemiology is changing and how important it is to use evidence-based classification when deciding on treatment (Torres et al., 2021).

Bacterial Pneumonia Definitions
Community-acquired pneumonia (CAP) is an acute infection of lung parenchyma that occurs outside of a hospital setting or within 48 hours of admission. Capsular aggregation happens a lot in healthy people, but it is worse in older people and those with a lot of health problems. HAP, or acute lung infection, can happen to a patient who is not intubated if it happens more than 48 hours after they are admitted to the hospital. HAP is more likely to cause infections that don't respond to treatment, which can make the disease worse and lead to more deaths because of the patient's illness and the hospital setting (Shoar and Musher, 2020).
It is hard to find atypical pneumonia pathogens using gram stains and bacterial cultures. Sometimes, infections with Mycoplasma pneumoniae, Chlamydophila pneumoniae, or Legionella pneumophila can cause less severe or non-classical respiratory symptoms. These infections can be hard to diagnose without special tests. Ventilator-associated pneumonia (VAP) symptoms may appear within 48 hours after endotracheal intubation in patients undergoing mechanical ventilation. VAP diminishes airway defenses and facilitates biofilm formation on the ventilator, presenting distinctive challenges for the prevention and treatment of high-risk infections (Carugati et al., 2020).

Figure 1: Pneumonia



Vital Signs
The physical exam shows that there is systemic disease and serious breathing problems. The patient's tachycardia (112 beats per minute) is a physiological stress response likely induced by fever, hypoxemia, and systemic inflammation; their elevated body temperature (38.8 °C) suggests an ongoing infectious process. It's clear that gas exchange is being blocked and breathing is getting harder because the person is breathing 28 times a minute. Acute infections often occur alongside hypotension (92/56 mmHg), potentially signifying circulatory dysfunction attributable to sepsis or relative hypovolemia. An oxygen saturation of 88% on room air confirms that the lungs are not getting enough oxygen, which means that hypoxemia is present and extra oxygen therapy is needed. These symptoms together point

to a systemic infection of the lower respiratory tract, which can be mild to severe and is a strong sign of severe community-acquired pneumonia (Yusuf S, and Camm., 2005).

Physical Examination

Upon examination, it was observed that the patient appeared significantly ill and was evidently struggling to breathe. The activation of auxiliary muscles indicated an elevation in the work of breathing. When the specialist listened to the chest, they heard less breath sounds in the right lower lung area and found that the area was not sensitive to percussion. The findings suggest the potential for pleural effusion and alveolar consolidation. There was a loud, coarse crackling sound in the same area, which means that there was fluid or inflammatory exudate in the alveolar gaps (Kalil et al., 2016).
During the cardiovascular evaluation, tachycardia was noted, but no audible murmurs were present, indicating that the patient may have been undergoing a compensatory physiological response to hypoxemia rather than a primary cardiac dysfunction. A benign abdominal examination was characterized by a soft, non-tender abdomen and the absence of organomegaly. Examination of the extremities revealed mild peripheral cyanosis and minor edema, indicating that the underlying lung disease was resulting in diminished oxygen supply (Kalil et al., 2016).

White blood cell count was 17,800/mm³, which means that they were having an acute inflammatory response that is consistent with an active infectious disease. Lab tests also showed significant leukocytosis. The significantly elevated levels of inflammatory biomarkers, such as a C-reactive protein (CRP) level of 200 mg/L and a procalcitonin concentration of 5.4 ng/mL, strongly indicated the presence of a severe bacterial infection, most likely pneumonia. The renal function tests showed that the kidneys weren't working properly at first, which could have been because of dehydration and low blood flow due to sepsis (Riley and Rupert., 2015).

The tests showed high blood urea nitrogen (28 mg/dL) and serum creatinine (1.6 mg/dL). A blood glucose level of 180 mg/dL was also noted, which is a typical stress-induced finding in diabetic individuals during acute infections; hyperglycemia was also identified. The arterial blood gas analysis showed significant hypoxemia, which means that the lungs weren't working well and the gas exchange wasn't happening well. This was shown by a PaO_2 of 58 mmHg on room air. These test results taken together point to a serious infection of the lower respiratory tract that is also causing systemic inflammation and early organ failure (Dabla., 2010).

Imaging

Imaging findings confirmed the medical history and physical examination results. Chest radiology revealed right lower lobe consolidation and pleural fluid accumulation, indicative of bacterial pneumonia with pleural involvement. A more thorough examination using computed tomography of the chest confirmed the presence of a parapneumonic effusion with lobar consolidation. The imaging results, along with the patient's history of shortness of breath and lack of responsiveness to percussion in the right lower lung field, suggest that the patient has community-acquired pneumonia with pleural effusion. This shows that the illness is getting worse and needs immediate and focused treatment (Torres et al., 2021).

Pathophysiology

People used to think that the lower respiratory system was clean, but new research has shown that it is actually a place where germs can grow. The body's natural and adaptive defenses usually stop the spread and growth of an infection when it reaches the alveoli. When the immune system isn't strong enough to keep infections from getting into the lung parenchyma and multiplying there, bacterial pneumonia can happen. Korkmaz and Traber (2023) state that the clinical signs of this disease are caused by the combination of bacterial pathogenicity and the host's inflammatory response.
There are many layers of protection in the respiratory system that work together to keep infections from happening. The nasal hairs and the mucociliary escalator catch and get rid of dirt and other things that don't belong in the body. Lysozyme, surfactant proteins A and D, antimicrobial peptides, and other substances that fight germs stick to them. Alveolar macrophages are the first line of defense in the immune system. Pattern recognition receptors like Toll-like receptors (TLRs) find bacterial fragments

and cause phagocytosis, which releases proinflammatory mediators. Phillips-Houlbracq et al. (2018) assert that this enhances the adaptive immune system and neutrophils in combating infections.
Bacteria in the alveoli make cytokines and chemokines. IL-1 and TNF-α cause hypothalamic fever, while IL-8 and G-CSF help neutrophils mature and leukocytosis happen. Gas exchange stops when inflammatory cells and plasma proteins get into the alveoli and block the alveolar-capillary barrier. This leads to hypoxemia. Some of the physical changes are low oxygen levels, fast breathing, trouble breathing, and a cough that brings up mucus (Peteranderl et al., 2017).
Virulence factors help pathogenic microbes get around the body's defenses. Streptococcus pneumoniae is the most common cause of community-acquired pneumonia. Phagocytes have a harder time digesting it because it has a polysaccharide capsule. When vascular permeability goes up, proteins and plasma can get into the alveolar gaps, making the lungs less flexible and making it hurt to breathe. When the pleura gets involved, it activates the somatic sensory fibers of the phrenic nerve, which causes severe pleuritic chest pain that gets worse when you breathe in. Severe infections can cause hemostasis by killing tissues and damaging capillaries (Brooks and Mias., 2018).
Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and some strange ones like Mycoplasma, Chlamydophila, and Legionella are the most common types of bacteria that can cause pneumonia in people. Parapneumonic effusion, empyema, lung abscess, and sepsis can happen if infections are not treated or are not managed well and spread beyond the alveoli. Bacterial infection and an uncontrolled inflammatory response in the host can lead to shock and organ dysfunction (Brown., 2012).
Bacterial pneumonia arises from a complex interplay between the pathogenicity of the infection and the host's immunological responses. Inflammation may seem helpful at first, but it actually causes problems throughout the body and makes the lungs hurt a lot. By knowing how these pathways work, we can better manage antimicrobial therapy, deal with problems more effectively, and improve patient outcomes by responding quickly and giving supportive care (Rider and Frazee, 2018).

Figure 2: Pathophysiology of pneumoniae



This patient was more likely to get a serious respiratory infection because they had chronic obstructive pulmonary disease (COPD) and type 2 diabetes mellitus. Chronic obstructive pulmonary disease (COPD) damages the respiratory epithelium, which makes it harder for the lungs to get rid of infections and secretions. Persistent airway inflammation damages the respiratory epithelium. Diabetes is an added risk factor because it weakens the immune system's neutrophil, cytokine, and immunological functions. Comorbidities make illness worse and last longer by helping bacteria grow and lowering the immune system (Karnati et al., 2021).
Low blood pressure and high lactate levels are two signs of sepsis. Sepsis causes problems with the circulatory system, which can lead to vasodilation throughout the body, increased permeability of capillaries, and decreased organ perfusion. To stop septic shock and the failure of many organs, serious infections, systemic inflammation, and poor perfusion must be diagnosed and treated quickly (Hotchkiss and Karl., 2003).

Management and Clinical Pharmacology

The IDSA/ATS (2019) and NICE (2024) guidelines say that when treating community-acquired pneumonia (CAP), doctors should think about how bad the symptoms are, how healthy the patient is overall, and what the medication might do to them. The recommended treatment for stable, non-severe CAP is either 100 mg of doxycycline twice a day or 1 g of amoxicillin three times a day. The goal of these drugs is to get rid of S. pneumoniae and H. influenzae. For severe CAP, pleural effusion, or sepsis, it is best to use a combination of treatments. It is common to give IV β-lactam antibiotics like ceftriaxone or ampicillin-sulbactam with macrolides like azithromycin or respiratory fluoroquinolones like levofloxacin.

Antibiotics work for a shorter amount of time (5–7 days) against minor infections than they do against more serious ones (14 days), like bacteremia or parapneumonic effusion. Supportive care includes giving oxygen to people with low blood oxygen levels, giving fluids through an IV to keep blood pressure stable, and giving pain and fever medications. Antibiotics in the β-lactam class kill bacteria by stopping them from making their cell walls. Immunomodulatory macrolides stop bacteria from making proteins and causing inflammation by binding to the 50S ribosomal subunit. Fluoroquinolones stop bacteria from copying their DNA by blocking DNA gyrase and topoisomerase IV. Research on pneumonia treatment shows that these drugs kill bacteria and keep patients stable (Khilnani et al., 2019).

Clinical Management

The patient received an empirical intravenous antibiotic regimen consisting of azithromycin (500 mg once daily) and ceftriaxone (2 g once daily) for a duration of seven days. This gave full protection against both common and rare respiratory pathogens that can cause serious cases of community-acquired pneumonia. At the same time, a lot of supportive care was started to help with problems with the whole body and the lungs. Supplemental oxygen via a nasal cannula at 2 L/min was used to treat hypoxemia, intravenous fluid therapy was used to keep hemodynamic stability, bronchodilator therapy was used to relieve airflow limitation caused by chronic obstructive pulmonary disease (COPD), and therapeutic drainage of the pleural effusion was used to remove infected exudate and re-expand infected lung tissue (Plouffe et al., 2000).

This patient with type 2 diabetes mellitus used a sliding-scale insulin regimen to keep their blood sugar levels in check and avoid stress-induced hyperglycemia and other problems that come with it. Metformin was temporarily withheld due to the heightened risk of acute kidney injury resulting from infection and dehydration. The combined therapy approach led to clinical improvement, which was shown by higher oxygen saturation, lower white blood cell count, and overall hemodynamic stabilization. Levofloxacin oral step-down medication (750 mg once daily for five days) was given at discharge to make sure the antimicrobial treatment was finished and microbiological control was still in place. This personalized, cross-disciplinary management method led to a good clinical outcome with few problems (Kaur et al., 2023).

Comparison

In general, the way therapy was done followed valid evidence-based practices and was in line with the most up-to-date clinical guidelines. The patient's kidney function and preexisting chronic obstructive pulmonary disease (COPD) were carefully considered to make sure that the patient would be safe while still getting the right care. Adopting and adhering to an oral fluoroquinolone regimen in the outpatient setting was evidently motivated by clinical pragmatism; this facilitated the completion of treatment while ensuring adequate antibacterial coverage. Importantly, no signs of antibiotic resistance were found during treatment. This means that the chosen regimen was not only appropriate, but it also worked to control microbiological parameters (Nardini et al., 2014).

Conclusion

In short, standardized treatment plans don't work for older people with community-acquired pneumonia, especially those with a lot of other health problems. An integrated and individualized strategy is essential. There is strong evidence that getting older, having COPD, and having diabetes mellitus make the condition worse, slow down the recovery process, and raise the risk of complications like sepsis and pleural effusion. This study emphasizes the importance of evidence-based antibiotic selection, prompt initiation of combination therapy in severe cases, and careful treatment modification based on renal

function, metabolic status, and overall clinical stability. It is possible to keep treatment effective while switching from intravenous to oral medicine if you use clinical response and microbiological data as guides. This change helps with good antimicrobial stewardship. Collaboration between different fields is very important for optimizing pharmacotherapy, keeping an eye on side effects, and making sure that care continues. This includes clinical pharmacists and advanced practice nurses who are actively involved. In the end, the best way to improve clinical outcomes and lower the death and illness rates from community-acquired pneumonia is to use patient-centered drug therapy that follows guidelines.

References

1. Anwar, Shehwaz, Fahad A. Alhumaydhi, Arshad Husain Rahmani, Vikalp Kumar, and Faris Alrumaihi. 2024. "A Review on Risk Factors, Traditional Diagnostic Techniques, and Biomarkers for Pneumonia Prognostication and Management in Diabetic Patients" Diseases 12, no. 12: 310. https://doi.org/10.3390/diseases12120310
2. Brooks LRK, Mias GI. Streptococcus pneumoniae's Virulence and Host Immunity: Aging, Diagnostics, and Prevention. Front Immunol. 2018 Jun 22;9:1366. doi: 10.3389/fimmu.2018.01366. PMID: 29988379; PMCID: PMC6023974.
3. Brown JS. Community-acquired pneumonia. Clin Med (Lond). 2012 Dec;12(6):538-43. doi: 10.7861/clinmedicine.12-6-538. PMID: 23342408; PMCID: PMC5922594.
4. Carugati, M., Aliberti, S., Sotgiu, G., Blasi, F., Gori, A., Menendez, R., Encheva, M., Gallego, M., Leuschner, P., Ruiz-Buitrago, S., Battaglia, S., Fantini, R., Pascual-Guardia, S., Marin-Corral, J., Restrepo, M. I., & GLIMP Collaborators. (2020). Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: An international point-prevalence study. European Journal of Clinical Microbiology & Infectious Diseases, 39(8), 1513–1525. https://doi.org/10.1007/s10096-020-03897-1
5. Dabla PK. Renal function in diabetic nephropathy. World J Diabetes. 2010 May 15;1(2):48-56. doi: 10.4239/wjd.v1.i2.48. PMID: 21537427; PMCID: PMC3083882.
6. Dinh, A., Barbier, F., Bedos, J.-P., Blot, M., Cattoir, V., Claessens, Y.-E., Duval, X., Fillâtre, P., Gautier, M., Guegan, Y., Jarraud, S., Le Monnier, A., Lebeaux, D., Loubet, P., de Margerie, C., Serayet, P., Tandjaoui-Lambotte, Y., Varon, E., Welker, Y., & Basille, D. (2025). Update of guidelines for management of community-acquired pneumonia in adults by the French Infectious Disease Society (SPILF) and the French-Speaking Society of Respiratory Diseases (SPLF): Endorsed by the French Intensive Care Society (SRLF), the French Microbiology Society (SFM), the French Radiology Society (SFR), and the French Emergency Society (SFMU). Respiratory Medicine and Research, 87, 101161. https://doi.org/10.1016/j.resmer.2025.101161
7. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003 Jan 09;348(2):138-50. [PubMed] [Reference list]
8. Jain, V., Vashisht, R., Yilmaz, G., et al. (2025). Pneumonia pathology. In StatPearls [Internet]. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK526116/
9. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O'Grady NP, Bartlett JG, Carratalà J, El Solh AA, Ewig S, Fey PD, File TM, Restrepo MI, Roberts JA, Waterer GW, Cruse P, Knight SL, Brozek JL. Executive Summary: Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016 Sep 01;63(5):575-82
10. Karnati S, Seimetz M, Kleefeldt F, Sonawane A, Madhusudhan T, Bachhuka A, Kosanovic D, Weissmann N, Krüger K, Ergün S. Chronic Obstructive Pulmonary Disease and the Cardiovascular System: Vascular Repair and Regeneration as a Therapeutic Target. Front Cardiovasc Med. 2021 Apr 12;8:649512. doi: 10.3389/fcvm.2021.649512. PMID: 33912600; PMCID: PMC8072123.
11. Kaur, A., Sharma, G. S., & Kumbala, D. R. (2023). Acute kidney injury in diabetic patients: A narrative review. Medicine (Baltimore), 102(21), e33888. https://doi.org/10.1097/MD.0000000000033888
12. Khilnani, G. C., Zirpe, K., Hadda, V., Mehta, Y., Madan, K., Kulkarni, A., Mohan, A., Dixit, S., Guleria, R., & Bhattacharya, P. (2019). Guidelines for antibiotic prescription in intensive care unit.

Indian Journal of Critical Care Medicine, 23(Suppl 1), S1–S63. https://doi.org/10.5005/jp-journals-10071-23101
13. Korkmaz, F. T., & Traber, K. E. (2023). Innate immune responses in pneumonia. Pneumonia, 15(1), 4. https://doi.org/10.1186/s41479-023-00123-4
14. Mahapatra S, Heffner AC. Septic Shock. [Updated 2023 Jun 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430939/
15. Metlay, J.P., Waterer, G.W., Long, A.C., Anzueto, A., Brozek, J., Crothers, K., ... & Whitney, C.G. (2019). Diagnosis and treatment of adults with community-acquired pneumonia: An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Clinical Infectious Diseases, 68(6), e1–e45.
16. Nardini S, Annesi-Maesano I, Del Donno M, Delucchi M, Bettoncelli G, Lamberti V, Patera C, Polverino M, Russo A, Santoriello C, Soverina P. The AIMAR recommendations for early diagnosis of chronic obstructive respiratory disease based on the WHO/GARD model*. Multidiscip Respir Med. 2014 Sep 3;9(1):46. doi: 10.1186/2049-6958-9-46. PMID: 25473523; PMCID: PMC4252853.
17. NICE. (2024). Pneumonia in adults: Diagnosis and management (NG138). National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ng138
18. Peteranderl C, Sznajder JI, Herold S, Lecuona E. Inflammatory Responses Regulating Alveolar Ion Transport during Pulmonary Infections. Front Immunol. 2017 Apr 18;8:446. doi: 10.3389/fimmu.2017.00446. PMID: 28458673; PMCID: PMC5394420.
19. Phillips-Houlbracq, M., Ricard, J. D., Foucrier, A., Yoder-Himes, D., Gaudry, S., Bex, J., Messika, J., Margetis, D., Chatel, J., Dobrindt, U., Denamur, E., & Roux, D. (2018). Pathophysiology of Escherichia coli pneumonia: Respective contribution of pathogenicity islands to virulence. International Journal of Medical Microbiology, 308(2), 290–296. https://doi.org/10.1016/j.ijmm.2018.01.004
20. Plouffe J, Schwartz DB, Kolokathis A, Sherman BW, Arnow PM, Gezon JA, Suh B, Anzuetto A, Greenberg RN, Niederman M, Paladino JA, Ramirez JA, Inverso J, Knirsch CA. Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. The Azithromycin Intravenous Clinical Trials Group. Antimicrob Agents Chemother. 2000 Jul;44(7):1796-802. doi: 10.1128/AAC.44.7.1796-1802.2000. PMID: 10858333; PMCID: PMC89964.
21. Rider, A. C., & Frazee, B. W. (2018). Community-acquired pneumonia. Emergency Medicine Clinics of North America, 36(4), 665–683. https://doi.org/10.1016/j.emc.2018.07.001
22. Riley LK, Rupert J. Evaluation of Patients with Leukocytosis. Am Fam Physician. 2015 Dec 01;92(11):1004-11.
23. Shoar, S., & Musher, D. M. (2020). Etiology of community-acquired pneumonia in adults: A systematic review. Pneumonia, 12, 11. https://doi.org/10.1186/s41479-020-00072-7
24. Torres A, Cilloniz C, Niederman MS, Menéndez R, Chalmers JD, Wunderink RG, van der Poll T. Pneumonia. Nat Rev Dis Primers. 2021 Apr 08;7(1):25
25. Torres, A., Cilloniz, C., Niederman, M. S., Menéndez, R., Chalmers, J. D., Wunderink, R. G., & van der Poll, T. (2021). Pneumonia. Nature Reviews Disease Primers, 7(1), 25. https://doi.org/10.1038/s41572-021-00264-0
26. Yusuf S, Camm AJ. Deciphering the sinus tachycardias. Clin Cardiol. 2005 Jun;28(6):267-76.